

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

02200

315756

| | |
|--|---|
| <p>Licensee</p> <p>1. SIRA Imaging Center, L.L.C.</p> <p>2. P.O. Box 4366 Bloomington, IN 47402-4366</p> | <p>In accordance with the letter dated August 26, 2006,</p> <p>3. License number 13-24646-02 is amended in its entirety to read as follows:</p> <p>4. Expiration date September 30, 2010</p> <p>5. Pocket No. 030-35415 Reference No.</p> |
|--|---|

- | | | |
|---|--|---|
| <p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 31.11</p> <p>D. Any byproduct material permitted by 10 CFR 35.300</p> | <p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Prepackaged Kits</p> <p>D. Any (excluding iodine-131 for thyroid carcinoma)</p> | <p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As needed</p> <p>B. As needed</p> <p>C. As needed</p> <p>D. As needed</p> |
|---|--|---|

9. Authorized Use:
- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
 - B. Any imaging and localization study permitted by 10 CFR 35.200.
 - C. In vitro studies.
 - D. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300 (excluding iodine-131 for thyroid carcinoma).

CONDITIONS

- 10. Licensed material shall be used only at the licensee's facilities located at 500 Landmark Avenue, Bloomington, Indiana.
- 11. The Radiation Safety Officer for this license is Mark Bisesi, M.D.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
13-24646-02

Docket or Reference Number
030-35415

Amendment No. 8

12. Licensed material is only authorized for use by, or under the supervision of:

- A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
- B. The following individuals are authorized users for medical use as indicated:

| <u>Authorized Users</u> | <u>Material and Use</u> |
|-----------------------------|---|
| Douglas D. Geiger, M.D. | 10 CFR 35.100, 35.200 and 31.11. |
| Phillip R. Doering, M.D. | 10 CFR 35.100, 35.200 , 35.300 (excluding iodine-131 for thyroid carcinoma) and 31.11. |
| Bruce N. Monson, M.D. | 10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma) and 31.11. |
| George K. Wolfer, Jr., M.D. | 10 CFR 35.100, 35.200 , 35.300 (excluding iodine-131 for thyroid carcinoma) and 31.11. |
| Mark A. Bisesi, M.D. | 10 CFR 35.100, 35.200 , 35.300 (excluding iodine-131 for thyroid carcinoma) and 31.11. |
| Neal David Abdullah, M.D. | 10 CFR 35.100, 35.200 and 31.11. |
| Sean M. Flynn, M.D. | 10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma) and 31.11. |
| Bharati R. Kharkar, M.D. | 10 CFR 35.300 (excluding iodine-131 for thyroid carcinoma) and 31.11. |
| David Y. Lee, M.D. | 10 CFR 35.300 (excluding iodine-131 for thyroid carcinoma) and 31.11. |
| Todd A. Winkler, M.D. | 10 CFR 35.100 and 35.200. |
| T. L. Megremis, M.D. | 10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma) and 31.11. |
| Chris W. McGary, M.D. | 10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for thyroid carcinoma) and 31.11. |
| Winston Brooks Davis, M.D. | 10 CFR 35.100, 35.200 and 31.11. |


13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
13-24646-02Docket or Reference Number
030-35415

Amendment No. 8


15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated June 21, 2000 (with attachments, excluding QMP negative declaration dated June 19, 2000); and
- B. Letters dated August 16, 2001 (except the Quality Management Program) and January 9, 2004.



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date DEC 19 2006

By


William P. Reichhold
Materials Licensing Branch
Region III